ES2188586T3 - Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura. - Google Patents

Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.

Info

Publication number
ES2188586T3
ES2188586T3 ES93109742T ES93109742T ES2188586T3 ES 2188586 T3 ES2188586 T3 ES 2188586T3 ES 93109742 T ES93109742 T ES 93109742T ES 93109742 T ES93109742 T ES 93109742T ES 2188586 T3 ES2188586 T3 ES 2188586T3
Authority
ES
Spain
Prior art keywords
profilaxis
therapy
purpura
preparation
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93109742T
Other languages
English (en)
Inventor
Jurgen Romisch
Eric-Paul Paques
Robert Bartlett
Gerhard Dickneite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Application granted granted Critical
Publication of ES2188586T3 publication Critical patent/ES2188586T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A LA APLICACION DE INHIBIDORES DE COMPLEMENTO PARTICULARMENTE DE INACTIVADOR C1 O LOS FACTORES I O H, PARA PRODUCIR UNOS MEDICAMENTOS PARA PROFILAXIS Y TERAPIA DE ENFERMEDADES INTESTINALES INFLAMABLES CRONICAS, ENFERMEDADES DE LA PIEL INFLAMATORIAS Y PURPURA.
ES93109742T 1992-07-09 1993-06-18 Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura. Expired - Lifetime ES2188586T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4222534A DE4222534A1 (de) 1992-07-09 1992-07-09 Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura

Publications (1)

Publication Number Publication Date
ES2188586T3 true ES2188586T3 (es) 2003-07-01

Family

ID=6462826

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93109742T Expired - Lifetime ES2188586T3 (es) 1992-07-09 1993-06-18 Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.

Country Status (12)

Country Link
US (1) US6248365B1 (es)
EP (1) EP0585552B1 (es)
JP (1) JP3776940B2 (es)
KR (1) KR100300798B1 (es)
AT (1) ATE231885T1 (es)
AU (1) AU671835B2 (es)
CA (1) CA2100212C (es)
DE (2) DE4222534A1 (es)
ES (1) ES2188586T3 (es)
HU (1) HU220599B1 (es)
MX (1) MX9304110A (es)
TW (1) TW272940B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
US8088579B2 (en) * 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
US8911733B2 (en) * 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
US7329030B1 (en) 2006-08-17 2008-02-12 Augux., Ltd. Assembling structure for LED road lamp and heat dissipating module
SI3028716T1 (sl) * 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
DK2379066T3 (da) * 2008-09-16 2014-06-30 Imunek Farma Ilaç Sanayi Ve Ticaret A S Anvendelse af opioidantagonister til fremstilling af et lægemiddel til behandling af retinadegenerationssygdomme
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
US8323670B2 (en) * 2009-10-01 2012-12-04 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Topical compositions of opioid antagonists and methods for treating skin conditions therewith
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
AU2012311483B2 (en) 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor
CN104080474B (zh) 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
WO2014131865A1 (en) 2013-02-28 2014-09-04 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
US10532087B2 (en) 2015-06-03 2020-01-14 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
KR102715222B1 (ko) * 2016-02-19 2024-10-11 에어 워터 가부시키가이샤 화합물 반도체 기판, 펠리클막, 및 화합물 반도체 기판의 제조 방법
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja) 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
KR102060891B1 (ko) 2018-05-23 2019-12-30 유승선 가미사물탕을 유효성분으로 포함하는 색소성자반증 예방 또는 치료용 조성물
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2617202A1 (de) * 1976-04-20 1977-11-03 Troponwerke Dinklage & Co Oligopeptide als komplementhemmer
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5157019A (en) * 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
EP0353941A3 (en) * 1988-08-02 1991-05-02 Takeda Chemical Industries, Ltd. Medicament for psoriasis containing derivatives of 3-aminopyrazolo [3,4-d]pyrimidine
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Also Published As

Publication number Publication date
KR100300798B1 (ko) 2001-10-22
HU9301978D0 (en) 1993-09-28
US6248365B1 (en) 2001-06-19
AU4180593A (en) 1994-01-13
DE59310327D1 (de) 2003-03-06
KR940005285A (ko) 1994-03-21
EP0585552A1 (de) 1994-03-09
DE4222534A1 (de) 1994-01-13
ATE231885T1 (de) 2003-02-15
MX9304110A (es) 1994-03-31
CA2100212A1 (en) 1994-01-10
AU671835B2 (en) 1996-09-12
CA2100212C (en) 2005-03-08
EP0585552B1 (de) 2003-01-29
TW272940B (en) 1996-03-21
JPH06157342A (ja) 1994-06-03
JP3776940B2 (ja) 2006-05-24
HU220599B1 (hu) 2002-03-28
HUT65754A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
MX9304110A (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento destinado a la profilaxis y a la terapia de enfermedades intestinales y cutaneas inflamatorias asi como de purpura.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2169719T3 (es) Derivados de maleinimida y su utilizacion como medicamento.
CL2021000793A1 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ES513357A0 (es) "un sistema terapeutico bajo la forma de un vendaje para administrar el medicamento".
ES2080307T3 (es) Composiciones farmaceuticas.
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
ES2176197T3 (es) Sistema de administracion transdermal que contiene un acido acetilsalicilico para la terapia de trombosis y la profilaxis del cancer.
MX9303799A (es) Derivados de la serie de vitamina d con modificaciones en la posicon 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la prod.
ES2114588T3 (es) Forma farmaceutica de un gel acuoso que contiene un retinoide.
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
ES2184131T3 (es) Derivados de benzamidina y su utilizacion como medicamentos con efecto antagonista de ltb4.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
ES2192680T3 (es) Nuevos derivados de vitamina d con sustituyentes carbo- o heterociclicos en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
MX9304793A (es) Glicanas de actividad inmunoestimulante.
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
ES2177671T3 (es) Benzamida enterocinetica.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2081476T3 (es) Uso de acidos grasos especificos en la fabricacion de un medicamento para su suministro por iontoforesis.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.